BioSpace News Archive

According to Nova one advisor, The U.S. Commercial Restoration Waterproofing Membranes market size was valued at US$ 750.9 million in 2021 and is expected to hit US$ 2.04 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.9% from 2022 to 2030.

According to Nova one advisor, during the forecast period of 2022 to 2030, The U.S. Acids market size was valued at US$ 6.45 billion in 2021 and is expected to hit US$ 11.6 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030.

According to Nova one advisor, The U.S. Medical Billing Outsourcing market size was valued at US$ 4.9 billion in 2021 and is expected to hit US$ 12.7 billion by 2030, growing at a compound annual growth rate (CAGR) of 11.35% from 2022 to 2030.

The global artificial organ and bionics market was estimated at USD 25.4 billion in 2021 and it is expected to surpass around USD 70.1 billion by 2030, poised to grow at a CAGR of 11.94% from 2022 to 2030.

The global anti-snoring devices and snoring surgery market size was estimated at around USD 1.45 billion in 2021 and it is projected to hit around USD 2.8 billion by 2030, growing at a CAGR of 7.59% from 2022 to 2030.

According to Vision Research Reports, the global coronary stents market was valued at USD 8.8 billion in 2021 and it is predicted to surpass around USD 12.3 billion by 2030 with a CAGR of 3.79% from 2022 to 2030.

The National Human Genome Research Institute, part of the National Institutes of Health, and the National Science Teaching Association have partnered to ignite genetic and genomic curiosity in students through a new, multi-year initiative that will provide research-based instructional resources and professional learning experiences to high school educators nationwide.

The global myopia and presbyopia treatment market was estimated at USD 16.5 billion in 2021 and it is expected to surpass around USD 33.9 billion by 2030, poised to grow at a CAGR of 8.33% from 2022 to 2030.

A sensor-equipped computer program can accurately identify and count arm movements in people undergoing stroke rehabilitation, a new study shows.

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering of 17,899,698 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 3,030,302 shares of its common stock at an exercise price of $0.01 per share.